SOPH

SOPHiA GENETICS SA is a healthcare company operating in the health information services industry. With a market capitalization of $312.10 million, it ranks within the smaller end of the sector's scale. The company has a revenue of $73.30 million and employs 423 individuals. The financials of SOPHiA GENETICS SA reveal significant challenges. The net income (TTM) is -$74,978,000, indicating substantial losses. The operating margin is -91.8% and the profit margin is -102.3%, further highlighting the company's difficulties in generating profits. Returns on equity and assets are also negative at -86.1% and -25.6%, respectively. The debt-to-equity ratio of 104.43 suggests a significant reliance on debt financing. Valuation metrics for SOPHiA GENETICS SA include a forward P/E of -5.23, indicating potential future losses or declining earnings. The price to book is 5.15 and the price to sales is 4.26, suggesting that investors are valuing the company based on its assets and revenue. However, the revenue growth rate (YoY) is 22.8%, which may be a positive factor in the company's valuation context.